267 related articles for article (PubMed ID: 11099375)
21. Crystal structure of the SH3 domain of betaPIX in complex with a high affinity peptide from PAK2.
Hoelz A; Janz JM; Lawrie SD; Corwin B; Lee A; Sakmar TP
J Mol Biol; 2006 Apr; 358(2):509-22. PubMed ID: 16527308
[TBL] [Abstract][Full Text] [Related]
22. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs.
Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA
J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402
[TBL] [Abstract][Full Text] [Related]
23. Ligand-induced structural changes to maltodextrin-binding protein as studied by solution NMR spectroscopy.
Evenäs J; Tugarinov V; Skrynnikov NR; Goto NK; Muhandiram R; Kay LE
J Mol Biol; 2001 Jun; 309(4):961-74. PubMed ID: 11399072
[TBL] [Abstract][Full Text] [Related]
24. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src.
Gonfloni S; Weijland A; Kretzschmar J; Superti-Furga G
Nat Struct Biol; 2000 Apr; 7(4):281-6. PubMed ID: 10742171
[TBL] [Abstract][Full Text] [Related]
25. Crystallographic structure of the SH3 domain of the human c-Yes tyrosine kinase: loop flexibility and amyloid aggregation.
Martín-García JM; Luque I; Mateo PL; Ruiz-Sanz J; Cámara-Artigas A
FEBS Lett; 2007 May; 581(9):1701-6. PubMed ID: 17418139
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of PxxDY motif recognition in SH3 binding.
Aitio O; Hellman M; Kesti T; Kleino I; Samuilova O; Pääkkönen K; Tossavainen H; Saksela K; Permi P
J Mol Biol; 2008 Sep; 382(1):167-78. PubMed ID: 18644376
[TBL] [Abstract][Full Text] [Related]
27. Solution structure and dynamics of G1TE, a nonphosphorylated cyclic peptide inhibitor for the Grb2 SH2 domain.
Lou YC; Lung FD; Pai MT; Tzeng SR; Wei SY; Roller PP; Cheng JW
Arch Biochem Biophys; 1999 Dec; 372(2):309-14. PubMed ID: 10600169
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of the C-terminal SH2 domain of the p85alpha regulatory subunit of phosphoinositide 3-kinase: an SH2 domain mimicking its own substrate.
Hoedemaeker FJ; Siegal G; Roe SM; Driscoll PC; Abrahams JP
J Mol Biol; 1999 Oct; 292(4):763-70. PubMed ID: 10525402
[TBL] [Abstract][Full Text] [Related]
29. Orienting domains in proteins using dipolar couplings measured by liquid-state NMR: differences in solution and crystal forms of maltodextrin binding protein loaded with beta-cyclodextrin.
Skrynnikov NR; Goto NK; Yang D; Choy WY; Tolman JR; Mueller GA; Kay LE
J Mol Biol; 2000 Feb; 295(5):1265-73. PubMed ID: 10653702
[TBL] [Abstract][Full Text] [Related]
30. Quantitative comparison of the hydrogen bond network of A-state and native ubiquitin by hydrogen bond scalar couplings.
Cordier F; Grzesiek S
Biochemistry; 2004 Sep; 43(35):11295-301. PubMed ID: 15366939
[TBL] [Abstract][Full Text] [Related]
31. Why ligand cross-reactivity is high within peptide recognition domain families? A case study on human c-Src SH3 domain.
He P; Wu W; Wang HD; Liao KL; Zhang W; Lv FL; Yang K
J Theor Biol; 2014 Jan; 340():30-7. PubMed ID: 24021866
[TBL] [Abstract][Full Text] [Related]
32. NMR solution structure of the inserted domain of human leukocyte function associated antigen-1.
Legge GB; Kriwacki RW; Chung J; Hommel U; Ramage P; Case DA; Dyson HJ; Wright PE
J Mol Biol; 2000 Feb; 295(5):1251-64. PubMed ID: 10653701
[TBL] [Abstract][Full Text] [Related]
33. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
Lange G; Lesuisse D; Deprez P; Schoot B; Loenze P; Bénard D; Marquette JP; Broto P; Sarubbi E; Mandine E
J Med Chem; 2003 Nov; 46(24):5184-95. PubMed ID: 14613321
[TBL] [Abstract][Full Text] [Related]
34. NMR studies of unfolded states of an SH3 domain in aqueous solution and denaturing conditions.
Zhang O; Forman-Kay JD
Biochemistry; 1997 Apr; 36(13):3959-70. PubMed ID: 9092826
[TBL] [Abstract][Full Text] [Related]
35. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of a glutamate/aspartate binding protein complexed with a glutamate molecule: structural basis of ligand specificity at atomic resolution.
Hu Y; Fan CP; Fu G; Zhu D; Jin Q; Wang DC
J Mol Biol; 2008 Sep; 382(1):99-111. PubMed ID: 18640128
[TBL] [Abstract][Full Text] [Related]
37. Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis.
Gonfloni S; Frischknecht F; Way M; Superti-Furga G
Nat Struct Biol; 1999 Aug; 6(8):760-4. PubMed ID: 10426955
[TBL] [Abstract][Full Text] [Related]
38. SH3 domains and drug design: ligands, structure, and biological function.
Dalgarno DC; Botfield MC; Rickles RJ
Biopolymers; 1997; 43(5):383-400. PubMed ID: 9566119
[TBL] [Abstract][Full Text] [Related]
39. Conformational and dynamics changes induced by bile acids binding to chicken liver bile acid binding protein.
Eberini I; Guerini Rocco A; Ientile AR; Baptista AM; Gianazza E; Tomaselli S; Molinari H; Ragona L
Proteins; 2008 Jun; 71(4):1889-98. PubMed ID: 18175325
[TBL] [Abstract][Full Text] [Related]
40. Prediction of binding affinities between the human amphiphysin-1 SH3 domain and its peptide ligands using homology modeling, molecular dynamics and molecular field analysis.
Hou T; McLaughlin W; Lu B; Chen K; Wang W
J Proteome Res; 2006 Jan; 5(1):32-43. PubMed ID: 16396493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
